Last edition
News about "licensing agreement"
Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea
Pursuant to the licence agreement, Ocugen will receive upfront license fees and near-term development milestones equaling up to USD 7.5 million. The company will be entitled to sales milestones of USD 1.5 million for every USD 15 million of sales in Korea, projected to reach USD 180 million or more in the first 10 years of commercialisation.
Licensing Agreement | 17/09/2025 | By Dineshwori
Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against the collaboration targets.
Licensing Agreement | 05/01/2024 | By Manvi | 386
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy